Skip to content

A randomized controlled trial of esketamine in subanesthetic doses to improve the quality of early recovery after robot-assisted laparoscopic radical prostatectomy in elderly patients: effects on cognitive function and anxiety and depression symptoms

A randomized controlled trial of esketamine in subanesthetic doses to improve the quality of early recovery after robot-assisted laparoscopic radical prostatectomy in elderly patients: effects on cognitive function and anxiety and depression symptoms

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127848
Enrollment
Unknown
Registered
2026-07-08
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Group E (esketamine group):Low opioid anesthesia with esketamine
Group C (conventional opioid group):Conventional opioid anesthesia

Sponsors

Dalian Municipal Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients planned to undergo elective robot-assisted laparoscopic radical prostatectomy under general anesthesia; 2. Age between 60 and 85 years old; 3. BMI 18-28 kg/m^2; 4. ASA class I to III; 5. Agree to participate in this study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. People with a history of opioid abuse or long-term use of opioids/sedatives; 2. Those with serious respiratory depression, an acute exacerbation of chronic obstructive pulmonary disease, status asthmaticus, or other relative contraindications to opioids; 3. Those with severe liver or kidney dysfunction; 4. People with central nervous system injuries, a history of mental illness, or preoperative cognitive/hearing impairments making assessment difficult; 5. Anyone allergic to esketamine or the anesthetics involved in this study; 6. Those with serious cardiovascular disease, uncontrolled hypertension, or hyperthyroidism; 7. Cases where researchers believe there might be other anesthesia risks or situations making participation in this study inappropriate.

Design outcomes

Primary

MeasureTime frame
QoR-40 Scale Score;

Secondary

MeasureTime frame
Hospital Anxiety and Depression Scale (HADS) score (including anxiety [HADS-A] and depression [HADS-D] subscales);The total number of compressions, and salvage analgesia rate of Patient Controlled Intravenous Analgesia (PCIA) pump;Montreal Cognitive Assessment (MoCA) score;Hemodynamic parameters (heart rate, mean arterial pressure, pulse oximetry);Dosage of propofol, remifentanil, and sufentanil, as well as the use of central vascular drugs during surgery;Incidence of postoperative adverse reactions;Postoperative recovery related indicators;Visual Analog Scale (VAS) pain rating in resting and exercise (cough) states;the incidence of hypotension and bradycardia;Ramsay Sedation Rating;incidence of anxiety and depression;

Countries

China

Contacts

Public ContactLiping Han

Dalian Municipal Central Hospital

han651310@163.com+86 411 8441 2001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026